Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia
10.3760/cma.j.issn.0253-2727.2017.03.003
- VernacularTitle: 首次获骨髓无白血病状态时血细胞恢复程度在成人急性髓系白血病患者中的预后意义
- Author:
Xin REN
1
;
Ting ZHAO
;
Jing WANG
;
Honghu ZHU
;
Hao JIANG
;
Jinsong JIA
;
Shenmiao YANG
;
Bin JIANG
;
Debing WANG
;
Xiaojun HUANG
;
Qian JIANG
Author Information
1. Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China
- Publication Type:Journal Article
- Keywords:
Leukemia, myeloid, acute;
Remission induction;
Blood cell count;
Prognosis
- From:
Chinese Journal of Hematology
2017;38(3):185-191
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore prognostic significance of blood count at the time of achieving first morphologic leukemia-free state[complete remission (CR, ANC ≥1×109/L and PLT ≥100×109/L) , CR with incomplete PLT recovery (CRp) and CR with incomplete ANC and PLT recovery (CRi) ]in adult patients with de novo acute myeloid leukemia (AML) .
Methods:From January 2008 to February 2016, data of consecutive newly-diagnosed AML (non-APL) adults who received continuous chemotherapy in our hospital were analyzed retrospectively.
Results:352 patients were included in the study. 179 (50.9%) were male. Median age was 44 (17-65) years. Using the SWOG cytogenetic classification, 87 (24.7%) , 171 (48.6%) , 46 (13.1%) and 48 (13.6%) patients belonged to favorable, intermediate, unfavorable and unknown categories, respectively. 16 (4.5%) had monosomal karyotype and 41 (11.6%) had FLT3-ITD mutation positive. Best response achieved at the time of achieving first morphologic leukemia-free state was CR in 299 (84.9%) patients, CRp in 26 (7.4%) and CRi in 27 (8.1%) . With a median follow-up period of 16 (2-94) months in survivors, the probabilities of cumulative incident of relapse (CIR) rate, disease free survival (DFS) and overall survival (OS) at 30 months were 47.5%, 46.0% and 58.6%, respectively. Multivariate analyses showed that non-CR (CRp or CRi) , was associated with high relapse rate, shorter DFS and OS. In addition, intermediate or high risk of SWOG cytogenetic classification and FLT3-ITD positive were common unfavorable factors affecting CIR, DFS and OS. Peripheral blast ≥60% at diagnosis was adverse factors affecting DFS. Age ≥48 years and bone marrow blasts ≥67% were associated with shorter OS.
Conclusion:Blood count at the time of achieving morphologic leukemia-free state was one of the key markers associated with treatment outcomes in adults with AML.
